Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
via fortune.com
Short excerpt below. Read at the original source.
Novo Nordisk A/S Chief Executive Officer Mike Doustdar says the company’s blockbuster obesity drugs could ultimately pull it into increasingly buzzy areas of healthcare, from longevity research to aesthetic medicine. “We have to be obsessed with what our patients want,” Doustdar said Sunday in an interview at the American Diabetes Association conference in New Orleans. […]